{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:56:52Z","timestamp":1779245812423,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jcjd.2014.05.001","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T16:31:25Z","timestamp":1412267485000},"page":"364-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies"],"prefix":"10.1016","volume":"38","author":[{"given":"Julie A.","family":"Lovshin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2014.05.001_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","author":"Sivertsen","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","article-title":"Cardiovascular effects of gliptins","volume":"10","author":"Scheen","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib7","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.2513","article-title":"Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells","volume":"17","author":"Ellingsgaard","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jcjd.2014.05.001_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jcjd.2014.05.001_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.05.001_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/0-387-32824-6_1","article-title":"Peptide substrates of dipeptidyl peptidases","volume":"575","author":"Brandt","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2014.05.001_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.beem.2009.03.005","article-title":"Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP","volume":"23","author":"Mentlein","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A\u00a0role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jcjd.2014.05.001_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.jcjd.2014.05.001_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.jcjd.2014.05.001_bib16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","article-title":"Neuroprotective properties of GLP-1: Theoretical and practical applications","volume":"27","author":"Holst","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcjd.2014.05.001_bib17","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcjd.2014.05.001_bib18","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2337\/db08-0121","article-title":"Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity","volume":"57","author":"Cabou","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2014.05.001_bib19","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2337\/db11-0464","article-title":"Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-delta","volume":"60","author":"Cabou","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2014.05.001_bib20","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/en.2009-1197","article-title":"Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor","volume":"151","author":"Ban","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcjd.2014.05.001_bib21","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jcjd.2014.05.001_bib22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.regpep.2011.01.003","article-title":"GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes","volume":"167","author":"Tomas","year":"2011","journal-title":"Regul Pept"},{"issue":"Suppl","key":"10.1016\/j.jcjd.2014.05.001_bib23","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1016\/j.amjcard.2011.03.046","article-title":"Cardiovascular effects of glucagonlike peptide-1 agonists","volume":"108","author":"Davidson","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","article-title":"Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials","volume":"28","author":"Fonseca","year":"2014","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jcjd.2014.05.001_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2012.04214.x","article-title":"Investigation of the haemodynamic effects of exenatide in healthy male subjects","volume":"74","author":"Mendis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib26","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.05.001_bib27","doi-asserted-by":"crossref","first-page":"e001986","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcjd.2014.05.001_bib28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1463-1326.2012.01609.x","article-title":"Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide","volume":"14","author":"Paul","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jcjd.2014.05.001_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/dom.12175","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: A meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/ajh.2009.245","article-title":"Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes","volume":"23","author":"Okerson","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jcjd.2014.05.001_bib33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.05.001_bib35","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcjd.2014.05.001_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","article-title":"One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial","volume":"65","author":"Pratley","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jcjd.2014.05.001_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.05.001_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1620\/tjem.223.133","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes","volume":"223","author":"Ogawa","year":"2011","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.jcjd.2014.05.001_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","article-title":"Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats","volume":"21","author":"Yu","year":"2003","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jcjd.2014.05.001_bib40","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000094334","article-title":"Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans","volume":"73","author":"Gutzwiller","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.jcjd.2014.05.001_bib42","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrneph.2013.272","article-title":"The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes?","volume":"10","author":"Muskiet","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib44","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2014.05.001_bib45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jcjd.2014.05.001_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EC-13-0087","article-title":"Glucagon-like peptide-1: Effect on pro-atrial natriuretic peptide in healthy males","volume":"3","author":"Skov","year":"2014","journal-title":"Endocr Connect"},{"key":"10.1016\/j.jcjd.2014.05.001_bib47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-13-36","article-title":"Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients","volume":"13","author":"Li","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib48","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated through the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jcjd.2014.05.001_bib49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.05.001_bib50","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2014.05.001_bib51","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.diabres.2013.11.014","article-title":"Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor agonists","volume":"103","author":"Dubois-Laforgue","year":"2014","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267114001920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267114001920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:26:01Z","timestamp":1761492361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267114001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1499267114001920"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2014.05.001","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2014.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}